Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H25NO2 |
| Molecular Weight | 263.3752 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC[C@@H](O)C1=CC(OCC2CCCCC2)=CC=C1
InChI
InChIKey=WJIGGYYSZBWCGC-MRXNPFEDSA-N
InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1
Emixustat (formerly ACU-4429) is a nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium protein 65 (RPE65). Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway RPE65. Acucela Inc., a Kubota Pharmaceutical company, is developing emixustat for the treatment of Stargardt disease and proliferative diabetic retinopathy.
Originator
Approval Year
Sample Use Guides
Phase ii, randomized, placebo-controlled, study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration: Subjects were randomly assigned to oral emixustat (2, 5, 7, or 10 mg once daily) or placebo (3:1 ratio) for 90 days.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
548816
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1141777-14-1
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
C171669
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
02DZ1HBF0M
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
Emixustat
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
DB12608
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
XX-163
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
9576
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
DTXSID50150665
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
25221720
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107821
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY | |||
|
100000177199
Created by
admin on Sat Dec 16 01:27:18 GMT 2023 , Edited by admin on Sat Dec 16 01:27:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
